In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Prognostic impact of invasive hemodynamic evaluation in patients with pulmonary arterial hypertension

Session Poster session 3

Speaker Ines Aguiar Ricardo

Event : ESC Congress 2017

  • Topic : hypertension
  • Sub-topic : Hypertension
  • Session type : Poster Session

Authors : I Aguiar-Ricardo (Lisbon,PT), R Placido (Lisbon,PT), I Goncalves (Lisbon,PT), J Agostinho (Lisbon,PT), G Lima Da Silva (Lisbon,PT), M Nobre-Menezes (Lisbon,PT), AR Francisco (Lisbon,PT), R Santos (Lisbon,PT), A Ferreira (Lisbon,PT), T Guimaraes (Lisbon,PT), S Robalo Martins (Lisbon,PT), J Fauto Pinto (Lisbon,PT)

Authors:
I. Aguiar-Ricardo1 , R. Placido1 , I. Goncalves1 , J. Agostinho1 , G. Lima Da Silva1 , M. Nobre-Menezes1 , A.R. Francisco1 , R. Santos1 , A. Ferreira1 , T. Guimaraes1 , S. Robalo Martins1 , J. Fauto Pinto1 , 1Hospital Universitário de Santa Maria/CHLN, CAML, CCUL,Faculdade de Medicina, Universidade de Lisboa, Cardiology - Lisbon - Portugal ,

Citation:
European Heart Journal ( 2017 ) 38 ( Supplement ), 557

Introduction: Invasive hemodynamic evaluation is a fundamental diagnostic method in patients with pulmonary hypertension (PH). However, its prognostic value in this group of patients is not fully established.

Purpose: To assess the prognostic impact of hemodynamic parameters of right catheterization in patients with PH.

Methods: Prospective observational study of patients with PH undergoing right and left catheterization for diagnostic confirmation and functional evaluation during vasoreactivity test. Only patients with mean pulmonary arterial pressure (PAP) >25 mmHg considered not secondary to left heart disease were included. A basal evaluation of the conventional hemodynamic parameters, left and right ventricular function indexes, pulmonary and systemic vascular resistance indexes were performed and they were re-evaluated during vasoreactivity test. The parametres were analysed and related with overall mortality and with cardiac death or hospitalization during clinical follow-up by Multivariate regression analysis of Cox.

Results: A total of 68 patients were included (71% females, mean age 53±17 years), 81% of whom were from group 1 (NICE) and 15% from group IV. The mean value of mean pulmonary artery pressure was 47±16mmHg and mean right atrial pressure was 11±7mmHg. During a median follow-up of 34 months, 7 patients (10%) died and 25 (37%) were hospitalized for heart failure. Of all hemodynamic parameters, the only independent predictor of mortality was the mean right atrial pressure, for each 1mmHg rise, mortality risk increased by 12% (hazard ratio (HR): 1, 12; 95% CI 1.02–1.23; p=0.018) and the risk of death or hospitalization for cardiac causes was 17% (HR: 1.17, 95% CI: 1.00–1.37, P=0.050). The prognosis was not influenced by the demonstration of pulmonary arterial vasoreactivity, magnitude of PAP elevation or pulmonary vascular resistance.

Conclusion: In patients with PH, invasive hemodynamic evaluation offers an addictional value in prognostic stratification. In particular, measurement of mean right atrial pressure has been shown to be an independent predictor of mortality. On the other hand, other parameters such as pulmonary arterial vasoreactivity, although important in the definition of the therapeutic strategy, did not have an impact on the risk of death or hospitalization.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are